Network meta-analysis of targeted therapies for diffuse large B cell lymphoma

Wang, Jie; Huang, Jun; Zeng, Qing

doi:10.1186/s12885-020-07715-2

Cited by 3 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diffuse large B-cell lymphoma (DLBCL) accounts for 30–35% of newly diagnosed B-cell lymphomas ( 5 ). Although DLBCL is curable with first-line treatment of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in >60% of patients, the remaining patients develop relapsed/refractory (RR) disease.…”

Section: Introductionmentioning

confidence: 99%

Hemophagocytic lymphohistiocytosis as an onset of diffuse large B‑cell lymphoma: A case report

et al. 2022

View full text Add to dashboard Cite

A 53-year-old male presented with a 1-month history of hyperpyrexia. The clinical manifestations revealed hemophagocytic lymphohistiocytosis (HLH). Although a lymph node biopsy could not be obtained, a bone marrow biopsy revealed the activated B-cell subtype of diffuse large B-cell lymphoma (DLBCL). After being treated with HLH-1994 (dexamethasone and etoposide), a rituximab-containing chemotherapy and target agents involving bortezomib, the patient achieved remission. To understand the molecular profile of patient, next-generation sequencing and MYD88 L265P mutation examinations were performed, and the patient was determined to be positive for the MYD88 L265P mutation. Reports of DLBCL with plasmacytic differentiation and a MYD88 innate immune signal transduction adaptor L265P mutation concurrent with HLH are rare. Early recognition, precise diagnosis and timely therapy are pivotal in improving patient prognosis. Furthermore, molecular profiling enables researchers to develop potential therapies aimed at the activated NF-κB and endoplasmic reticulum stress signaling pathways. The present study highlights this pathogenesis and provides suggestions for further individualized therapeutics.

show abstract

Section: Introductionmentioning

confidence: 99%

Hemophagocytic lymphohistiocytosis as an onset of diffuse large B‑cell lymphoma: A case report

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Since bortezomib was then approved as the first effective proteasome inhibitor for multiple myeloma by the US Food and Drug Administration (FDA) in 2003, the median overall survival has been improved to more than 55 months [7]. A meta-analysis demonstrated that a bortezomibbased treatment regimen significantly benefited about overall survival, progression-free survival, and response rate [4,[8][9][10]. Therefore, bortezomib is still a pivotal drug in the treatment of multiple myeloma.…”

Section: Introductionmentioning

confidence: 99%

Relationship between Serum Bortezomib Concentration and Emergence of Diarrhea in Patients with Multiple Myeloma and/or AL Amyloidosis

Fujimoto

Ueno

Oda

et al. 2021

Cancers

View full text Add to dashboard Cite

(1) Background: multiple myeloma patients have benefited from bortezomib therapy, though it has often been discontinued owing to diarrhea. The objective of this study was to verify serum bortezomib concentration in the emergence of diarrhea. (2) Methods: this prospective, observational case-control, and monocentric study was performed with an approval by the Ethics Committee of Kumamoto University Hospital in 2015 (No. 1121) from February 2015 to April 2017. (3) Results: twenty-four patients with bortezomib therapy were recruited; eight patients (33.3%) developed diarrhea at day 3 as median. Median measured trough bortezomib concentration at 24 h after first or second dose for patients with or without diarrhea was 0.87 or 0.48 ng/mL, respectively (p = 0.04, Wilcoxon signed rank test). Receiver operation characteristic (ROC) analysis produced the cut-off concentration of 0.857 ng/mL (area under the ROC curve of 0.797, sensitivity of 0.625, specificity of 0.875). The survival curves between patients with and without diarrhea were similar (p = 0.667); those between patients with higher and lower concentration than median value (0.61 ng/mL) were also similar (p = 0.940). (4) Conclusions: this study indicated the possible involvement of serum bortezomib concentration in the emergence of diarrhea in bortezomib therapy in patients with multiple myeloma.

show abstract